Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate [defined as total number of patients with complete and partial response divided by number of response-evaluable patients] based on predetermined evaluation criteria
Each 49 day course of treatment until withdrawal or unacceptable toxicity
No
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Japan: Pharmaceuticals and Medical Devices Agency
CA139-372
NCT01024101
January 2004
December 2005
Name | Location |
---|